民生领域经营者集中审查三年审结950件

Core Viewpoint - The State Administration for Market Regulation (SAMR) has completed a three-year antitrust enforcement campaign in the livelihood sector, concluding 950 cases, with 3 conditionally approved and 1 prohibited, to maintain fair competition in key areas related to public welfare such as pharmaceuticals, utilities, and food [1][2]. Group 1: Antitrust Enforcement Results - SAMR has reviewed a number of significant merger cases in the livelihood sector, including the conditional approval of the acquisition of Tobi Pharmaceutical's equity by Xiansheng Pharmaceutical and the prohibition of Wuhan Yutong's acquisition of Shandong Huatai Pharmaceutical's equity [1]. - The enforcement actions have effectively maintained market competition and protected consumer interests [1]. Group 2: Market Competition Assessment - SAMR has conducted assessments of market competition in key livelihood sectors such as rail transit, pharmaceutical retail, medical devices, and new energy vehicles, dynamically monitoring the concentration of operators in the pharmaceutical industry [1]. - The assessments analyze industry characteristics and competition status, providing strong support for the review of operator concentrations in relevant livelihood sectors [1]. Group 3: Improvement of Review Processes - SAMR has enhanced the quality and efficiency of operator concentration reviews by optimizing the antitrust business system for operator concentration, enabling full online processing [2]. - The implementation of a delegated review system and various training methods, such as merger review classes, aims to improve the professional capabilities of reviewers at both central and local levels [2].